200 related articles for article (PubMed ID: 16940810)
1. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
Olbert PJ; Hegele A; Kraeuter P; Heidenreich A; Hofmann R; Schrader AJ
Anticancer Drugs; 2006 Sep; 17(8):993-6. PubMed ID: 16940810
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A; Sternberg CN; Skoneczna I; Kovel S
BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
5. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
[TBL] [Abstract][Full Text] [Related]
7. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
Nelius T; Filleur S
Prostate; 2009 Dec; 69(16):1802-7. PubMed ID: 19676083
[TBL] [Abstract][Full Text] [Related]
8. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
Nelius T; Klatte T; de Riese W; Filleur S
Int Urol Nephrol; 2008; 40(1):97-104. PubMed ID: 17602304
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
14. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
18. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
19. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
[TBL] [Abstract][Full Text] [Related]
20. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
